CANCER IMMUNOTHERAPY PRINCIPLES AND PRACTICE

1. History of Cancer Immunotherapy
• SECTION I: BASIC PRINCIPLES OF TUMOR IMMUNOLOGY
2. Introduction to Basic Sciences—Cracking the Code of Cancer Immune Responsiveness and the Evolution of Cancer Biology
3. Human Tumor Antigens Recognized by T Lymphocytes
4. HLA Class I Antigen-Processing Machinery in Cancer
5. Systems Biology of T Cells
6. Activation of CD4+ T Lymphocytes
7. Regulation of Cell-Mediated Immunity: The Biology of Checkpoints and Regulatory T Cells
8. The Role of Breg Cells in Modulating the Antitumor Immune Response
9. The Innate Immune System: Natural Killer Cells
10. The Innate Immune System: Macrophages
11. Natural Killer Cell Effector Mechanisms Against Solid Tumors and Leukemias and Their Exploitation in Immunotherapy
12. Role of the Microbiota in Homeostasis, Carcinogenesis, and Therapy
13. Chemokines and Chemokine Receptors: Regulators of the Balance Between Antitumor and Protumor Immunity and Promising Targets in Cancer Immunotherapy
14. Role of the Tumor Microenvironment
• SECTION II: CANCER IMMUNOTHERAPY TARGETS AND CLASSES
15. Introduction to Principles of Cancer Immunotherapy
16. Manipulating Innate Immune Pathways as Cancer Immunotherapy
17. Cancer Vaccines: Considerations of Antigen, Formulation, and Delivery
18. T Cell Modulatory Cytokines
19. Adoptive T Cell Transfer
20. Immunotherapy Based on Blocking T Cell Inhibitory Pathways
21. Agonistic Antibodies to Co-Stimulatory Molecules
22. Immune Effects of Conventional Cancer Therapeutics
23. Oncolytic Viruses
24. Principles of Combination Immunotherapies
• SECTION III: IMMUNE FUNCTION IN CANCER PATIENTS
25. Introduction to Immune Function in Cancer Patients
26. Tumor-Infiltrating Immune Cells of Myeloid Origin
27. Intratumoral Gene Signatures and Host Genetic Variations Associated With Immune Responsiveness
28. Impact of Somatic Mutations on the Local and Systemic Antitumor Immune Response
29. Tumor Antigen Profiling
30. Assessment of Antitumor Immunity in Blood and Lymph Nodes
31. Regulatory T Cell Biology and Its Application in Cancer
32. Systemic Measures of Immune Function in Cancer Patients: Other Suppressive Cellular Mechanisms
33. Circulating Mediators of Tumor-Induced Immune Suppression
34. The Multifaceted Roles of B Cells and Plasma Cells in Antitumor Immunity
35. Systems Immunology Approaches to Cancer Immunotherapy
36. Tumor Microenvironment Metabolism as a Primordial Checkpoint in Antitumor T Cell Immunity
37. Age-Related Immune Function Changes as They Relate to Cancer Immunotherapy
38. Clinical Measures: Imaging, Pseudoprogression, and Metabolism
• SECTION IV: DISEASE-SPECIFIC TREATMENTS AND OUTCOMES
39. Introduction: General Approach to Cancer Immunotherapy—Lessons Learned From the Past Years
40. Immunotherapy in Melanoma
41. Other Cutaneous Tumors: Basal Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, and Merkel Cell Carcinoma
42. Immunotherapy in Genitourinary Malignancies
43. Immunotherapy in Gastrointestinal Cancers
44. Immunotherapy of Hepatocellular Carcinoma
45. Immunotherapy for Gynecologic Malignancies
46. Breast Cancer Immunotherapy
47. Lung Cancer
48. Head and Neck Cancer
49. Immunotherapy of Hematologic Malignancies: Lymphomas, Leukemias, and Myeloma
50. Brain Tumors
51. Sarcomas
52. Pediatric Cancers: Neuroblastoma
• SECTION V: REGULATORY ASPECTS OF CANCER IMMUNOTHERAPY
53. A Regulatory Perspective on Cell Therapy for Cancer: Chemistry, Manufacturing and Control, and Preclinical and Clinical Considerations
54. Gene Therapy-Based Immunotherapy Products for Human Clinical Trials: Chemistry, Manufacturing and Control, Preclinical and Clinical Considerations—An FDA Perspective
55. Regulatory Considerations for In Vitro Diagnostic Devices

“Drs. Butterfield, Kaufman and Marincola on behalf of the SITC have created a comprehensive must-have resource covering the basic and translational science behind approved and investigational immune therapies, and disease-by-disease clinical application of the therapies, written by leaders in the field. The textbook will be highly valuable reading for those just entering the field and for experienced scientists and clinicians looking to expand their knowledge base.” —Mario Sznol, MD, Professor of Medicine (Medical Oncology), Yale School of Medicine, New Haven, Connecticut
Cancer Immunotherapy Principles and Practice, from the Society for Immunotherapy of Cancer (SITC), is the authoritative reference on cancer immunobiology and the immunotherapy treatments that harness the immune system to combat malignant disease.
Featuring five sections and over 50 chapters covering the Basic Principles of Tumor Immunology, Cancer Immunotherapy Targets and Classes, Immune Function in Cancer Patients, Disease-Specific Treatments and Outcomes, and Regulatory Aspects of Cancer Immunotherapy, this book covers all major topics that have shaped the development of immunotherapy and propelled it to its current place at the forefront of cancer treatment innovation.
This volume is a comprehensive resource for oncologists and fellows, immunologists, cancer researchers, and related practitioners seeking understanding of the basic science and clinical applications of cancer immunotherapy. As well as presenting the evidence for immune-based cancer treatment, it positions immunotherapy in the context of other available cancer treatments and provides data on response rates, risks, and toxicities across a variety of diseases. Filled with detailed tables, and instructive illustrations, as well as key points for quick reference, Cancer Immunotherapy Principles and Practice simplifies a challenging and dynamic subject.

KEY FEATURES
• Clearly summarizes the basic principles and research supporting cancer immunotherapy clinical translation
• Contains expert guidance and treatment strategies for all immunotherapy classes and agents, including cell-based therapies, monoclonal antibodies, cytokine therapies, checkpoint inhibitors, oncolytic viruses, adjuvant approaches, and treatment combinations
• Includes expert perspectives from leading authorities in the field
• Provides information on all FDA-approved immunotherapies, including clinical management and outcome data
• Discusses clinical aspects of immunotherapy for individual cancer types, including melanoma and other skin cancers, lung cancers, gynecologic cancers, gastrointestinal cancers, hematologic cancers, genitourinary cancers, head and neck cancers, sarcomas, brain and other CNS cancers, breast cancer, and pediatric malignancies.
• Explains regulatory aspects behind the development and approval of immunotherapy drugs
• Includes Online Access to the Digital Book